ricochet64 / Shutterstock.com
Recent patent decisions in the life sciences sector are leading biotechnology companies to seek protection for their innovations by using alternatives to patents, with trade secrets the most viable, the BIO International Convention has heard.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
BIO 2015, trade secrets, biotech, DuPont, Michael Clarke, 2015 BIO International Convention